News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
News Bavarian and BMS press on with Opdivo and cancer vaccine com... BMS hopes combinations will maintain Opdivo lead after setback
News BMS' Opdivo stumbles in lung cancer, but could still maintai... Analysts expect Opdivo to recover via combination trials
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
